dream rais fair valu
take much dream clear view earn power
potenti fair valu one year today follow
year see thermo amazon laboratori equip billion
sale price power billion annual cash flow fulfil passion
acquisit estim re-posit portfolio busi pharma/
 revenu handili exceed organ growth guidanc
decad prior thermo industri would grow low singl
digit howev effort build higher/less cyclic growth profil manag
shift market focu achiev pharma biotech exposur benefit
proven global growth deceler yet beat expect
growth busi drive billion cash flow expect
addit catalyst could drive increment earn well
reiter buy rate rais fv
fundament higher growth stori thermo day low-single-digit
growth guidanc better organ growth seem visibl given
improv busi mix pharma/biotech pb repres even larger
piec pie vs remain singl
import increment growth driver compani estim price-to-book
segment grow quarterli past quarter drive
growth alon geograph basi china repres second
import growth driver achiev critic mass vs
divers china battl headwind like slower growth tariff
govern re-organ maintain histor pace
bioprocess drive biopharma growth underli pharma/biotech
revenu growth highlight transform occur
trillion pharmaceut market biolog continu becom greater
percentag global therapeut sale continu benefit base
end-to-end offer product servic discoveri commerci
thermo bioproduct busi media sut equip grow
recent quarter thermo billion revenu
lss bioproduct exposur doubl sinc even
larger publicli trade pure-play like sartoriu
rgen-buy view busi alon can/ha drive
bp total compani growth
manag acquisit patheon brammerbio
vertic integr compani boost exposur pharma
servic segment servic attribut total compani
revenu bn rel five year ago
coverag lonza lonn-swx-buy key competitor patheon/bramm
see double-digit growth market pharma continu focu
develop complex biopharmaceut includ cell gene
therapi would impli midpoint estim drive
bp increment growth compani level ultim estim
revenu drive bp midpoint
long-term growth guid
addit note analysi includ assumpt
respect lead posit ms/lc discoveri develop qa/
qc therapeut life scienc reagent bioscienc genet solut
tool lead us believ long term guidanc readili achiev
china strength amid headwind china valu life scienc tool lst
market never underst remain second-largest geograph market
routin report double-digit growth group howev
come without challeng saw slower growth trade war
tension rise food ministri reorgan govern crackdown
gener drug price despit numer headwind report
low-to-mid teen growth back compar china
repres half thermo emerg market exposur total
compani revenu compar revenu thermo
unmatch scale breadth product portfolio technic leadership align
chines govern initi transform economi one
base manufactur one base scienc technolog
dream includ lot flexibl
billion per year introduc quarter outer year model
repres attribut ex brammer even though manag
earmark nearli bn capit deploy next three
year estim deploy billion billion revenu
achiev histor margin increment ep possibl
assum sustain level increas dividend payout mn/yr
share repurchas activ bn ep build
bn addit cash flow model suggest reason
execut full bn author key variabl size
time free cash flow gener never fail impress
estim grow par earn nearli bn
fair valu rais fv estim base
continu visibl organ growth cash flow balanc sheet prime
earn accret past two year thermo trade averag
ebitda fv assum multipl min net debt place
upon ebitda fv reach
multipl ep minu net debt rel
averag ep view trade premium rel
peer averag ep given visibl organ growth
potenti earn accret current bake
million except per share data
geograph total estim
total sale
amort intang
annual revenu break-out margin
revenu
total sale
revenu
